If alpha emitters are stronger, why is beta therapy such as Lu-177 still used more?

Potency is not the only consideration. Beta emitters such as Lu-177 PSMA-617 (Pluvicto) are FDA-approved, widely supplied, well understood, and their longer range provides a 'crossfire' effect useful for tumours with uneven receptor expression. Alpha emitters such as Ac-225 face limited global supply and higher cost, more complex dosimetry, and off-target effects from recoiling decay daughters (for example salivary-gland toxicity). The choice depends on the disease, prior treatment and the individual patient.

Clinical Explainer · Targeted Alpha Therapy

Why alpha emitters are about 5× more potent than beta emitters.

Q: Are alpha emitters really 5 times more potent than beta emitters?

Roughly, yes. For the same absorbed radiation dose, alpha particles kill cells more effectively than beta particles. This is measured as relative biological effectiveness (RBE), and for alpha emitters over beta emitters the RBE is commonly cited at around 5, with reported values ranging from about 5 to 10 depending on the cell type and the biological endpoint measured. So 'about 5 times more potent' is an accurate plain-language summary, not a fixed physical constant.

Q: What does linear energy transfer (LET) mean?

Linear energy transfer is how much energy a particle deposits per unit distance as it travels through tissue. Alpha particles are high-LET (roughly 80-100 keV per micrometre), while beta particles are low-LET (around 0.2 keV per micrometre). Higher LET means denser ionisation along the track, which causes more concentrated, harder-to-repair DNA damage.

Q: Why do alpha emitters cause more DNA damage?

Because alpha particles ionise densely along a short track, they create clustered, complex double-strand DNA breaks rather than the sparse, mostly single-strand breaks typical of beta radiation. Clustered double-strand breaks are far harder for the cell to repair, and alpha damage is also less dependent on oxygen and on the cell-cycle phase. The result is more reliable, less reparable killing of the targeted cell.

Q: Which alpha-emitter therapies are approved or available?

Radium-223 (Xofigo) was the first alpha-emitting therapy approved by the FDA (2013) for metastatic castration-resistant prostate cancer with symptomatic bone metastases, after the ALSYMPCA trial showed an overall-survival benefit. Other alpha approaches, including Ac-225 PSMA-617 for prostate cancer and actinium- or lead-212-based PRRT for neuroendocrine tumours, are investigational and delivered at experienced centres under informed-consent frameworks.

Q: Are alpha-emitter therapies more toxic?

They have a different toxicity profile rather than simply being more toxic. The short range can spare bone marrow and distant normal tissue, but recoiling decay daughters can migrate from the target and cause off-target effects — the salivary-gland dryness (xerostomia) seen with Ac-225 PSMA is the best-known example. Radium-223 has been notably well tolerated with low marrow toxicity. Toxicity is managed by patient selection, dosing and monitoring.

Q: Is alpha-emitter therapy available in India or at FMRI?

Yes. Alpha-emitter therapies, including Ac-225 PSMA for prostate cancer and alpha-PRRT for neuroendocrine tumours, are delivered at a small number of experienced theranostics centres in India including Fortis Memorial Research Institute, Sector 44, Gurugram, under the care of Dr. Ishita B. Sen and Dr. Dharmender Malik. Eligibility is decided by imaging, organ function and multidisciplinary review, with full informed consent. Contact the team on WhatsApp +91 8800 988936.

The radiobiology behind targeted alpha therapy — high linear energy transfer, the five-to-tenfold relative biological effectiveness of alpha over beta, clustered DNA double-strand breaks, and the very short range that concentrates the killing where it is wanted. With the clinical proof from radium-223 and Ac-225 PSMA. Every figure sourced.

Dr. Ishita B. Sen, MDDirector & Chief, Nuclear Medicine · FMRI

Published 18 June 2026

Reviewed by Dr. Dharmender Malik

11 min read

Dr. Ishita B. Sen, in her own words, on why alpha emitters out-punch beta emitters — the short version.

Last reviewed by Dr. Dharmender Malik on 18 June 2026 · this article reflects the published radiobiology literature and current clinical practice at FMRI Gurugram.

Introduction

In theranostics we treat cancer with two broad families of radiation. Beta emitters — like lutetium-177, the isotope in Pluvicto and in PRRT — are the established workhorses. Alpha emitters — like actinium-225 and radium-223 — are the harder-hitting newcomers. Patients and referring doctors often hear that “alpha is about five times more powerful than beta,” and ask what that really means. This article unpacks it: where the figure comes from, the physics and biology behind it, and what it does and does not change for treatment. Every number here is sourced to the published literature.

Are alpha emitters really 5× more potent?

AI Overview · plain answer

For the same absorbed radiation dose, alpha particles kill cancer cells far more effectively than beta particles. Radiobiologists measure this as relative biological effectiveness (RBE), and the RBE of alpha over beta emitters is commonly cited at around 5, with reported values from about 5 to 10 depending on the cell type and the biological endpoint measured^[3]. So “about five times more potent” is an accurate plain-language summary — not a single fixed physical constant, but a sound rule of thumb.

Two physical properties drive that potency: alpha particles deposit enormously more energy per unit distance (high linear energy transfer), and they travel only a tiny distance before stopping. The combination produces dense, hard-to-repair DNA damage exactly where the radioligand binds, and very little elsewhere^[1]. The rest of this article walks through each piece.

Alpha vs beta — the physics in plain terms

The difference starts with what the two particles actually are. A beta particle is a fast electron — very light, singly charged. An alpha particle is a helium nucleus — two protons and two neutrons, about 7,000 times heavier and doubly charged. A heavy, highly charged particle drags far more electrons off the atoms it passes, so it ionises densely and stops quickly^[1].

Property	Alpha emitter (e.g. Ac-225, Ra-223)	Beta emitter (e.g. Lu-177, Y-90)
Particle	Helium nucleus (heavy, charge +2)	Electron (light, charge −1)
Linear energy transfer (LET)	High — ~80–100 keV/µm	Low — ~0.2 keV/µm
Range in tissue	~50–100 µm (2–10 cell diameters)	~0.5–11 mm (many cell diameters)
DNA damage	Clustered double-strand breaks	Mostly single-strand, sparse breaks
Biological potency (RBE vs beta)	~5× (range ~5–10)	Reference (1×)

Linear energy transfer (LET) is the amount of energy a particle leaves behind per micrometre of travel. Alpha particles are high-LET (about 80–100 keV/µm); beta particles are low-LET (about 0.2 keV/µm) — a difference of several hundred-fold in energy density along the track^[1]^[2]. And alpha particles travel only 50–100 micrometres — a few cell diameters — whereas beta particles range from roughly half a millimetre to several millimetres^[1].

Where the “5×” comes from — relative biological effectiveness

High energy density translates into greater cell killing, and that is captured by relative biological effectiveness. RBE is the ratio of the dose of a reference radiation (a beta emitter, or external photons) to the dose of the radiation being tested that is needed to produce the same biological effect. A higher RBE means a smaller dose does the same job.

In a much-cited laboratory comparison of the alpha emitter actinium-225 against the beta emitter lutetium-177 — both attached to the same somatostatin-targeting molecule — the authors note that the RBE of alpha over beta particles is known to be in the range of 5 to 10^[3]. Independent in vivo work on alpha-emitting lead-212 found an RBE of about 4.7 against X-rays^[12]. This is why “roughly five times” is the usual shorthand.

An important nuance

RBE is not a single fixed number. It varies with the cell type, the dose, and which biological endpoint is measured (cell survival, chromosome breaks, tumour control). Quoting “about 5×, in a range of 5–10” is honest; quoting a precise universal multiplier is not. The practical message is simply that alpha radiation does far more biological damage per unit of absorbed dose than beta radiation^[2].

The DNA mechanism — clustered double-strand breaks

The reason alpha radiation is so much more potent comes down to the kind of damage it leaves in DNA. As Dr. Sen describes in the video above, a beta particle scatters its energy thinly, producing mostly single-strand breaks and isolated lesions that a cell can usually repair. An alpha particle deposits its energy in a dense track, producing clustered, complex double-strand breaks — several breaks packed into a short stretch of DNA — which are far harder for the cell’s repair machinery to mend^[3].

Two further advantages follow from high-LET damage:

Less dependent on oxygen. Low-LET beta and photon therapy works less well in poorly oxygenated (hypoxic) tumour regions; high-LET alpha damage is much less reduced by hypoxia^[2].
Less dependent on the cell cycle, and harder to repair between doses. Alpha-induced breaks are less affected by which phase of division a cell is in, and repair between fractions is diminished — so resistance mechanisms that blunt beta therapy matter less^[2].

In short, the same energy delivered as alpha radiation is simply more lethal to the targeted cell — and more reliably so — than the same energy delivered as beta radiation^[3].

Short range, high precision

The second half of the alpha advantage is geography. Because an alpha particle stops within a few cell diameters, its destructive energy is concentrated on the cell the radioligand binds and its immediate neighbours, with little reaching tissue further away^[1]. This makes alpha emitters especially suited to:

Micrometastatic disease — tiny clusters and single cells, where a short, intense burst of radiation is ideal and a long beta range would mostly miss^[3].
Sparing nearby normal tissue — for example, the bone marrow adjacent to skeletal tumour deposits, which a longer-range beta particle can irradiate unnecessarily^[2].

The trade is real, though. A beta emitter’s longer range produces a crossfire effect — radiation from one labelled cell also hits neighbours that express little or no target — which can be useful when receptor expression across a tumour is patchy. Range is therefore a tool to be matched to the disease, not simply “shorter is better.”

Proof in the clinic — radium-223 and Ac-225 PSMA

This is not only theory. The clearest real-world demonstration is radium-223 (Xofigo), the first alpha-emitting therapy approved by the FDA, in 2013, for metastatic castration-resistant prostate cancer with symptomatic bone metastases. In the pivotal ALSYMPCA trial of 921 patients, radium-223 improved median overall survival to 14.9 months versus 11.3 months with placebo (hazard ratio 0.70) — about a 30% reduction in the risk of death^[5]. Tellingly, older beta-emitting bone agents (strontium-89, samarium-153) had eased pain but never improved survival; the alpha emitter did^[5].

The same logic drives newer alpha radioligand therapy:

Ac-225 PSMA-617 for prostate cancer — the alpha counterpart of Lu-177 PSMA-617 (Pluvicto). First reported by Kratochwil and colleagues in 2016, it has shown meaningful responses even in patients who have progressed on beta Lu-177 therapy^[6]^[10]^[11]. See our detailed guide to alpha-PSMA therapy and the comparison Lu-177 versus Ac-225.
Alpha PRRT for neuroendocrine tumours — using actinium-225 or lead-212 in place of Lu-177, for selected patients. See actinium / alpha PRRT.

Actinium-225 itself is notable: it has a 9.9-day half-life and decays through a chain that releases four alpha particles per atom, multiplying the effect of a single binding event^[4]^[9].

The trade-offs — why beta is still first-line

If alpha is so much more potent, why is most radioligand therapy today still done with beta emitters? Because potency is only one factor, and the alpha advantage comes with real costs^[2]:

Approval and evidence. Lu-177 PSMA-617 (Pluvicto) and Lu-177 DOTATATE are FDA-approved with large randomised trials behind them^[7]. Most alpha radioligands beyond radium-223 remain investigational.
Supply and cost. Actinium-225 is a rare radionuclide with limited global production, making alpha therapy scarcer and more expensive per cycle^[4]^[8].
Recoiling daughters and off-target effects. When alpha emitters decay, the daughter atoms recoil and can drift away from the target, causing off-target damage — the salivary-gland dryness (xerostomia) seen with Ac-225 PSMA is the best-known example^[3].
Dosimetry is harder. The microscopic range of alpha particles makes dose calculation and toxicity prediction more complex than for beta therapy^[2].

The honest framing is not “alpha beats beta,” but that each is a precision tool. Beta therapy is the proven, available first-line option for most patients; alpha therapy is the harder-hitting choice for selected situations — bone-dominant disease, micrometastases, or progression after beta therapy.

The bottom line

Alpha emitters are roughly five times more biologically potent than beta emitters — an RBE commonly cited around 5, in a reported range of about 5–10^[3].
The reason is physics and biology: high LET (dense energy deposition) plus a very short range, producing clustered, hard-to-repair double-strand DNA breaks right where the radioligand binds^[1].
The clinical proof is real: radium-223 improved survival in prostate cancer with bone metastases where beta bone agents had not^[5], and Ac-225 PSMA shows responses after beta therapy fails^[6].
Potency is not the whole story. Beta therapy remains first-line for most patients on grounds of approval, supply, cost and predictable dosimetry; alpha therapy is chosen for specific situations^[2].

Important

This article is general medical and scientific information for patient and clinician education. It is not a treatment recommendation. Whether alpha- or beta-emitter therapy is appropriate depends on your specific cancer, imaging, prior treatment and organ function, and is decided in a multidisciplinary review with full informed consent.

"Patients hear ‘five times more powerful’ and assume alpha must always be better. It isn’t that simple. Alpha radiation truly does more biological damage per dose — the radiobiology is clear. But the right question is never which particle is stronger; it is which one fits this tumour, this imaging, and this patient. Sometimes that answer is alpha. Very often, today, it is still beta."

Dr. Ishita B. Sen, MD · Director & Chief, Nuclear Medicine, FMRI

Specialist consult · alpha vs beta therapy

Whether an alpha or beta radioligand therapy suits your situation depends on your cancer type, current PSMA or DOTATATE imaging, prior treatment and organ function. The nuclear medicine team at FMRI — Dr. Ishita B. Sen and Dr. Dharmender Malik — can review your case and explain the options.

Discuss alpha vs beta therapy · WhatsApp +91 8800 988936

For patients & referring clinicians

Frequently asked questions

Q01Are alpha emitters really 5 times more potent than beta emitters?

Roughly, yes. For the same absorbed dose, alpha particles kill cells more effectively than beta particles. This is measured as relative biological effectiveness (RBE), commonly cited at around 5 for alpha over beta, with reported values from about 5 to 10 depending on cell type and endpoint [3]. “About five times more potent” is an accurate summary, not a fixed constant.

Q02What is the difference between alpha and beta radiation in cancer therapy?

A beta particle is a fast electron — light, low charge, low ionisation density, range of a few millimetres (e.g. lutetium-177). An alpha particle is a helium nucleus — far heavier, doubly charged, very high ionisation density, range only 50–100 micrometres (a few cell diameters). The alpha deposits much more energy over a much shorter path, making it more biologically potent [1].

Q03What does linear energy transfer (LET) mean?

LET is how much energy a particle deposits per unit distance in tissue. Alpha particles are high-LET (about 80–100 keV/µm); beta particles are low-LET (about 0.2 keV/µm) [1][2]. Higher LET means denser ionisation along the track, causing more concentrated, harder-to-repair DNA damage.

Q04What is relative biological effectiveness (RBE)?

RBE is the ratio of the dose of a reference radiation (such as a beta emitter or photons) to the dose of the radiation being studied that produces the same biological effect. For alpha over beta the RBE is typically about 5 (range ~5–10), meaning a much smaller alpha dose achieves the same cell kill [3]. It is not a single fixed number — it varies with endpoint, cell type and dose.

Q05Why do alpha emitters cause more DNA damage?

Alpha particles ionise densely along a short track, creating clustered, complex double-strand DNA breaks rather than the sparse, mostly single-strand breaks of beta radiation. Clustered double-strand breaks are far harder to repair, and alpha damage is also less dependent on oxygen and on the cell-cycle phase — so the killing is more reliable [3][2].

Q06If alpha emitters are stronger, why is beta therapy (Lu-177) still used more?

Potency is not the only factor. Beta emitters such as Lu-177 PSMA-617 (Pluvicto) are FDA-approved, widely supplied and well understood, and their longer range gives a useful crossfire effect for tumours with uneven receptor expression [7]. Alpha emitters such as Ac-225 face limited supply, higher cost, harder dosimetry and off-target effects from recoiling decay daughters [4][3]. The best choice depends on the disease and the patient.

Q07Which alpha-emitter therapies are approved or available?

Radium-223 (Xofigo) was the first FDA-approved alpha therapy (2013) for mCRPC with symptomatic bone metastases, after ALSYMPCA showed a survival benefit [5]. Other alpha approaches — Ac-225 PSMA-617 for prostate cancer [6], and actinium- or lead-212-based PRRT for neuroendocrine tumours — are investigational and delivered at experienced centres under informed-consent frameworks.

Q08What is the range of an alpha particle compared with a beta particle?

An alpha particle travels only about 50–100 micrometres in tissue — roughly 2 to 10 cell diameters. Beta particles travel much further: Lu-177 betas up to about 2 millimetres and Y-90 betas up to roughly 11 millimetres [1]. The very short alpha range concentrates killing on the targeted cell and its immediate neighbours, sparing tissue further away.

Q09Are alpha-emitter therapies more toxic?

They have a different toxicity profile rather than being uniformly more toxic. The short range can spare bone marrow and distant tissue, but recoiling decay daughters can migrate and cause off-target effects — xerostomia (dry mouth) with Ac-225 PSMA is the best-known example [3]. Radium-223 has been notably well tolerated with low marrow toxicity [5]. Toxicity is managed by patient selection, dosing and monitoring.

Q10Is alpha-emitter therapy available in India or at FMRI?

Yes. Alpha-emitter therapies including Ac-225 PSMA for prostate cancer and alpha-PRRT for neuroendocrine tumours are delivered at a small number of experienced theranostics centres in India, including Fortis Memorial Research Institute, Sector 44, Gurugram, under Dr. Ishita B. Sen and Dr. Dharmender Malik. Eligibility is decided by imaging, organ function and multidisciplinary review with full informed consent. Contact the team on WhatsApp +91 8800 988936.

Citations & references

The figures above are sourced from the primary literature listed below. Each reference links to the journal page — open in a new tab to verify.

[1] McDevitt MR, Sgouros G, Sofou S. Targeted and Nontargeted α-Particle Therapies. Annu Rev Biomed Eng. 2018;20:73-93. View source ↗

[2] Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020;19(9):589-608. View source ↗

[3] Graf F, Fahrer J, Maus S, et al. DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy. PLoS One. 2014;9(2):e88239. View source ↗

[4] Morgenstern A, Apostolidis C, Bruchertseifer F. Supply and Clinical Application of Actinium-225 and Bismuth-213. Semin Nucl Med. 2020;50(2):119-123. View source ↗

[5] Parker C, Nilsson S, Heinrich D, et al. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer (ALSYMPCA). N Engl J Med. 2013;369(3):213-223. View source ↗

[6] Kratochwil C, Bruchertseifer F, Giesel FL, et al. ²²⁵Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2016;57(12):1941-1944. View source ↗

[7] Sartor O, de Bono J, Chi KN, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (VISION). N Engl J Med. 2021;385(12):1091-1103. View source ↗

[8] Eychenne R, Chérel M, Haddad F, et al. Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”. Pharmaceutics. 2021;13(6):906. View source ↗

[9] Poty S, Francesconi LC, McDevitt MR, et al. α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies—Part 1. J Nucl Med. 2018;59(6):878-884. View source ↗

[10] Sathekge M, Bruchertseifer F, Knoesen O, et al. ²²⁵Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2019;46(1):129-138. View source ↗

[11] Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with ²²⁵Ac-PSMA-617: Swimmer-Plot Analysis. J Nucl Med. 2018;59(5):795-802. View source ↗

[12] Howell RW, Goddu SM, Bishayee A, Rao DV. Radioprotection against the biological effects of alpha-particle emitters: relative biological effectiveness studies. (Alpha-particle RBE in vivo.) Radiat Res. View source ↗

About the Author

Dr. Ishita B. Sen

MBBS · MD (Nuclear Medicine) · DNB · Post-doctoral Fellowship, Memorial Sloan Kettering Cancer Center, New York

Director and Chief of Nuclear Medicine at Fortis Memorial Research Institute. Co-founder of Theranostic Physicians Private Limited (TPPL). Two decades of clinical practice in PSMA and DOTATATE imaging and in beta- and alpha-emitter radioligand therapy, with one of the largest Indian institutional experiences in theranostics.

Full profile → All publications Book a consult